SB 204741, , >98% (HPLC)
Application
SB 204741 has been used as a 5-hydroxytryptamine receptor 2B (Htr2B) antagonist: to inhibit Htr2b signaling to test its effect on hepatic stellate cell (HSC) activation in three-month-old adult zebrafishto test its effect on the inhibition of fluoxetine effects in depressive-like behavioral studies in miceto test its effect in reducing scratching behavior evoked by sertraline in mice
Biochem/physiol Actions
5-HT2B serotonin receptor antagonist.
SB 204741 reduces the synaptic facilitation induced by the low dose of buprenorphine in spinal C-fiber synapses.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
Packaging
10, 50 mg in glass bottle
| Colour | off-white to tan |
|---|---|
| Quality Level | 100 |
| InChI key | USFUFHFQWXDVMH-UHFFFAOYSA-N |
| InChI | 1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19) |
| Manufacturer | SIGMA-ALDRICH |
| Form | solid |
| Assay | >98% (HPLC) |
There are no downloads for this product.
